Why 2D product identity is becoming a serious compliance and patient safety conversation
Pakistan’s pharmaceutical industry is entering a new phase of product accountability.
For many years, pharmaceutical packaging was treated mainly as a labeling and regulatory presentation requirement. A medicine pack carried the product name, batch number, expiry date, registration details, manufacturer information, and other mandatory text.
That information still matters.
But the industry is now moving toward something deeper.
A medicine pack must not only display information.
It must become digitally identifiable.
It must be verifiable.
It must be traceable.
It must connect to a trusted system that can support compliance, supply chain visibility, medicine verification, recall readiness, and patient safety.
This is why DRAP’s direction around
2D Barcode and Serialization is important for Pakistan’s pharma sector. DRAP has stated that it is in the process of implementing 2-D Barcode along with serialization for pharmaceutical products.
At the center of this shift is
GS1 DataMatrix.
From Old Barcode Thinking to 2D DataMatrix Readiness
The traditional 1D barcode was useful for product identification, inventory movement, and basic scanning.
But pharma traceability needs more than product-type identification.
A medicine pack needs product-level accountability.
That means the system should be able to answer questions such as:
Which product is this?
Which batch does it belong to?
When does it expire?
What is its unique serial number?
Was this pack genuinely produced?
Has this serial number already been scanned?
Where did this product move?
Can it be verified before reaching the patient?
This is where 2D GS1 DataMatrix becomes much more powerful than old barcode thinking.
A GS1 DataMatrix can carry structured product information in a compact code. DRAP’s draft amendment document refers to a GS1 Data-Matrix 2D barcode encoding unique and global identification data, and it also refers to serialization using random numbers in the GS1 Data-Matrix.
For pharma, this is not just a printing change.
It is a digital identity shift.
What a GS1 DataMatrix Can Carry on a Medicine Pack
A serialized GS1 DataMatrix can connect important product data to a medicine pack.
In practical pharma use, this may include:
• GTIN
• Batch or lot number
• Expiry date
• Serial number
Each of these data points has a specific role.
The
GTIN identifies the product.
The
batch or lot number connects the pack to a production batch.
The
expiry date supports safety and lifecycle control.
The
serial number gives the individual pack a unique identity.
Together, these elements help move the industry from batch-level visibility toward pack-level verification.
That is a major step.
Because a batch tells us about a group of products.
A serial number tells us about one specific pack.
Why Secondary Packaging Matters
The medicine box is where this transformation becomes visible.
DRAP’s draft amendment material refers to GS1 Data-Matrix 2D barcode requirements on secondary packaging, along with GTIN, batch/lot, expiry date, and serial number information.
This matters because secondary packaging is the level most often handled across real pharmaceutical supply chains.
It is touched by:
• Packaging teams
• Quality teams
• Warehouses
• Distributors
• Pharmacies
• Regulators
• Verification systems
• Supply chain partners
When the secondary pack carries a serialized GS1 DataMatrix, it becomes easier to connect the physical medicine pack with its digital record.
That connection supports stronger control.
The manufacturer can manage which serial numbers were produced.
The warehouse can scan products before dispatch.
The distributor can verify received goods.
The regulator can expect better traceability discipline.
The pharmacy can support medicine verification.
And the patient benefits from a more trusted medicine supply chain.
Serialization Is the Real Change Behind the Code
It is easy to look at GS1 DataMatrix as a packaging symbol.
But the real transformation is serialization.
Serialization means assigning a unique identity to each individual medicine pack.
This creates a new level of accountability.
Without serialization, a code may only identify the product or batch.
With serialization, the system can identify the exact pack.
This supports:
• Anti-counterfeit protection
• Medicine verification
• Duplicate code detection
• Product recall precision
• Market surveillance
• Supply chain investigation
• Regulatory reporting readiness
• Patient safety
This is why pharma companies should avoid treating serialization as only a packaging-line project.
It is much bigger.
It affects data, systems, workflows, quality control, warehouse operations, regulatory functions, and business accountability.
The Real Challenge Is Not Printing the Code
Many pharmaceutical companies may think the main challenge is printing the GS1 DataMatrix on the medicine box.
Printing is important.
Code quality is important.
Scanner readability is important.
But the bigger challenge is the system behind the code.
A serialized 2D code needs reliable data management.
That includes:
• Product master data
• GTIN allocation
• Batch data
• Expiry data
• Serial number generation
• Code commissioning
• Rejection handling
• Rework controls
• Aggregation data
• Warehouse scanning
• Verification workflows
• Reporting readiness
• Secure system access
• Audit trails
If these foundations are weak, the printed code will not create real traceability.
A code only becomes valuable when it is connected to a reliable digital infrastructure.
Why DRAP Serialization Should Be Seen as a Strategic Opportunity
Compliance will naturally be the first reason many companies respond.
That is expected.
But DRAP’s 2D Barcode and Serialization direction should not only be seen as a regulatory pressure.
It should also be seen as a chance to modernize Pakistan’s pharmaceutical supply chain.
Proper serialization can help pharma companies improve:
• Product integrity
• Recall readiness
• Supply chain control
• Brand protection
• Distributor accountability
• Export readiness
• Market confidence
• Patient safety
• Regulatory trust
This is where the opportunity becomes bigger than compliance.
A well-built serialization system can help manufacturers strengthen both operational control and market credibility.
The companies that prepare early will have an advantage.
The companies that wait until the last moment may face rushed implementation, poor data quality, packaging-line disruption, and compliance pressure.
Practical Industry Insight
At ZAUQ Global, we increasingly observe that serialization projects succeed when companies treat them as enterprise transformation projects, not only as machine installation projects.
A printing system alone cannot deliver traceability.
A camera inspection system alone cannot deliver verification.
A software platform alone cannot solve poor data discipline.
The strongest serialization programs usually bring together:
• Regulatory leadership
• Packaging-line readiness
• Quality assurance
• IT systems
• Warehouse operations
• Supply chain teams
• Master data governance
• Senior management commitment
This is especially important in Pakistan’s pharma market, where companies may be at different stages of digital maturity.
Some manufacturers may already have advanced packaging lines and ERP systems.
Others may still rely heavily on manual workflows.
DRAP’s direction will push both types of companies toward better digital readiness.
But the implementation path will not be the same for everyone.
Each company will need to assess its own product portfolio, line capability, data maturity, operational risks, and compliance timeline.
A Practical Readiness Checklist for Pharma Companies
Before implementation pressure increases, pharmaceutical manufacturers should start preparing now.
A practical readiness checklist should include:
• Review DRAP’s 2D Barcode and Serialization direction
• Identify all affected SKUs and packaging levels
• Validate GS1 company prefix and GTIN allocation
• Clean product master data
• Define batch, expiry, and serial number structures
• Assess packaging-line coding capability
• Check printer and ink suitability for medicine cartons
• Add or upgrade vision inspection systems
• Plan rejection and rework workflows
• Select serialization software architecture
• Prepare aggregation strategy
• Integrate ERP, packaging line, warehouse, and reporting systems
• Train production, quality, regulatory, warehouse, and IT teams
• Test scan readability and data accuracy
• Build medicine verification readiness
This is not a one-day project.
Serialization readiness requires planning, testing, validation, training, and operational discipline.
The Future of Pharma Traceability in Pakistan
The future of pharma traceability in Pakistan will not stop at printing GS1 DataMatrix codes.
The next stage will likely involve stronger connections between serialization, aggregation, verification, regulatory reporting, warehouse scanning, and market-level medicine authentication.
Over time, pharma companies will need systems that can support:
• Pack-level medicine verification
• Aggregated carton and pallet movement
• Distributor-level visibility
• Faster recalls
• Suspicious activity detection
• Anti-counterfeit monitoring
• Patient-facing verification
• Data-driven regulatory confidence
This is how a medicine supply chain becomes more trusted.
Not because every pack has a code.
But because every pack can be connected to a reliable truth.
Where ZAUQ Global and Pharma Trax Fit In
At ZAUQ Global, we believe the future of pharmaceutical trust will depend on products that can be identified, serialized, verified, and traced with confidence.
Through Pharma Trax, our focus is on helping pharmaceutical companies build practical infrastructure for serialization, aggregation, track and trace, brand protection, medicine verification, and patient safety.
This includes connecting physical packaging operations with digital systems.
The goal is not only to place GS1 DataMatrix on medicine boxes.
The goal is to help create a connected ecosystem where medicine packs can move through the supply chain with stronger visibility, stronger accountability, and stronger trust.
Key Ideas
• DRAP’s 2D Barcode and Serialization direction is a major signal for Pakistan’s pharma industry.
• GS1 DataMatrix helps medicine packs carry structured product identity data.
• Serialization gives each medicine pack a unique identity.
• The real value is not only in the printed code, but in the system behind it.
• Pharma companies need to prepare packaging lines, data systems, quality workflows, warehouse processes, and verification readiness.
• Patient safety should remain the central reason for serialization and traceability.
Conclusion
Pakistan’s pharmaceutical industry is moving toward a more accountable future.
DRAP’s 2D Barcode and Serialization direction is not just a technical update.
It is a step toward safer medicine supply chains, stronger regulatory visibility, better product verification, and higher patient trust.
GS1 DataMatrix is the visible part of that transformation.
Serialization is the discipline behind it.
Traceability is the infrastructure that gives it value.
For pharma manufacturers, the time to prepare is now.
Not only because compliance is coming.
But because medicine trust depends on it.
Call to Action
Is your pharmaceutical business preparing for GS1 DataMatrix, serialization, aggregation, and medicine verification?
Explore how
Pharma Trax by ZAUQ Global can support your serialization and track-and-trace readiness.
Request a Pharma Trax consultation.
